Abstract
Background: Coronary artery bypass grafting (CABG) remains the standard of care for patients with coronary artery disease (CAD). Debate exists concerning several factors, which include percutaneous coronary intervention (PCI) vs. CABG, single vs. bilateral mammary artery grafts, radial artery vs. saphenous vein grafts, right internal mammary artery vs. radial artery grafts, endoscopic vs. open vein-graft harvesting, and on-pump vs. off- pump surgery.
Moreover, challenging is the management of diabetic patients with CAD undergoing CABG. This review reports current indications, practice patterns, and outcomes of CABG.
Methods: Randomized controlled trials comparing CABG to other therapeutical strategies for CAD were searched through MEDLINE, EMBASE, Cochrane databases, and proceedings of international meetings.
Results: Large multicenter randomized and observational studies (SYNTAX, BEST, PRECOMBAT, ASCERT) have reported excellent outcomes in CABG patients, with always fewer rates of operative mortality and major morbidity, than PCI. The 10-year follow-up of ARTS II trial showed no difference between single and bilateral mammary artery. BARI 2D, MASS II, CARDia, FREEDOM trials showed that CABG is the best choice for diabetic patients.
Conclusion: CABG still represents one of the most widespread major surgeries, with well-known benefits on symptoms and prognosis in patients with CAD. However, further studies and follow-up data are needed to validate these evidences.
Keywords: Coronary artery bypass graft, coronary artery bypass grafting, extracorporeal circulation, minimally invasive extracorporeal circulation, on-pump surgical revascularization, diabetic patients.
Graphical Abstract
[1]
Hillis LD, Smith PK, Anderson JL, et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; Society of Cardiovascular Anesthesiologists; Society of Thoracic Surgeons. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 58(24): e123-210.
[2]
Sousa-Uva M, Neumann FJ, Ahlsson A, et al. 2018 ESC Scientific Document Group. ESC/EACTS Guidelines on myocardial revascularization. Eur J Cardiothorac Surg 2018.
[http://dx.doi.org/10.1093/ejcts/ezy289]
[http://dx.doi.org/10.1093/ejcts/ezy289]
[3]
Gruentzig A. Results from coronary angioplasty and implications for the future. Am Heart J 1982; 103: 779-83.
[4]
Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503-16.
[5]
Hueb W, Lopes NH, Gersh BJ, et al. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): A randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2007; 115: 1082-9.
[6]
Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011; 364: 1607-16.
[7]
Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med 2016; 374: 1511-20.
[8]
Aldea GS, Bakaeen FG, Pal J, et al. The society of thoracic surgeons clinical practice guidelines on arterial conduits for coronary artery bypass grafting. Ann Thorac Surg 2016; 101: 801-9.
[9]
Head SJ, Borgermann J, Osnabrugge RL, et al. Coronary artery bypass grafting: Part 2--optimizing outcomes and future prospects. Eur Heart J 2013; 34: 2873-86.
[10]
Farkouh ME, Domanski M, Sleeper LA, et al. FREEDOM Trial investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012; 367: 2375-84.
[11]
Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013; 381: 629-38.
[12]
Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative effectiveness of revascularization strategies. N Engl J Med 2012; 366: 1467-76.
[13]
Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: A collaborative analysis of individual patient data from ten randomised trials. Lancet 2009; 373: 1190-7.
[14]
Ferguson TB Jr, Hammill BG, Peterson ED, et al. A decade of change-risk profiles and outcomes for isolated coronary artery bypass grafting procedures, 1990-1999: A report from the STS National Database Committee and the Duke Clinical Research Institute. Society of Thoracic Surgeons. Ann Thorac Surg 2002; 73: 480.
[15]
Kowalewski M, Pawliszak W, Raffa GM, et al. Safety and efficacy of miniaturized extracorporeal circulation when compared with off-pump and conventional coronary artery bypass grafting: Evidence synthesis from a comprehensive Bayesian-framework network meta-analysis of 134 randomized controlled trials involving 22 778 patients. Eur J Cardiothorac Surg 2016; 49(5): 1428-40.
[16]
Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/ AATS/PCNA/SCAI/STS guideline for the diagnosis and man- agement of patients with stable ischemic heart disease: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012; 60: e44-e164.
[17]
Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/ AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Thorac Cardiovasc Surg 2015; 149: e5-e23.
[18]
Aldea GS, Bakaeen FG, Pal J, et al. The Society of Thoracic Surgeons Clinical Practice Guidelines on Arterial Conduits for coronary artery bypass grafting. Ann Thorac Surg 2016; 101: 801-9.
[19]
Petrie MC, Jhund PS, She L, et al. STICH Trial Investigators. Ten-year outcomes after coronary artery bypass grafting according to age in patients with heart failure and left ventricular systolic dysfunction: an analysis of the extended follow-up of the STICH Trial (Surgical treatment for ischemic heart failure). Circulation 2016; 134(18): 1314-24.
[20]
Holmes DR Jr, Davis KB, Mock MB, et al. The effect of medical and surgical therapy on subsequent sudden cardiac death in patients with coronary artery disease: A report from the Coronary Artery Surgery Study. Circulation 186(73): 1254-63.
[21]
Pigott JD, Kouchoukos NT, Oberman A, et al. Late results of surgical and medical therapy for patients with coronary artery disease and depressed left ventricular function. J Am Coll Cardiol 1985; 5: 1036-45.
[22]
Hammermeister KE, DeRouen TA, Murray JA, et al. Effect of aortocoronary saphenous vein bypass grafting on death and sudden death: Comparison of nonrandomized medically and surgically treated cohorts with comparable coronary disease and left ventricular function. Am J Cardiol 39: 925-34.
[23]
Daemen J, Boersma E, Flather M, et al. Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials. Circulation 2008; 118: 1146-54.
[24]
Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med 2013; 368: 254-65.
[25]
Head SJ, Milojevic M, Daemen J, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: A pooled analysis of individual patient data. Lancet 2018; 391(10124) Review. Erratum in: Lancet 2018 Aug 11; 392(10146): 476.
[26]
Head SJ, Davierwala PM, Serruys PW, et al. Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: Final five-year follow-up of the SYNTAX trial. Eur Heart J 2014; 35: 2821-30.
[27]
Park SJ, Ahn JM, Kim YH, et al. BEST Trial Investigators. Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med 2015; 372(13): 1204-12.
[28]
Shahian DM, O’Brien SM, Sheng S, et al. Predictors of long-term survival after coronary artery bypass grafting surgery: Results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database (the ASCERT study). Circulation 2012; 125(12): 1491-500.
[29]
Ranasinghe I, Alprandi-Costa B, Chow V, et al. Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007. Am J Cardiol 2011; 108: 617-24.
[30]
Fukui T, Tabata M, Morita S, Takanashi S. Early and long-term outcomes of cor- onary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris. J Thorac Cardiovasc Surg 2013; 145: 1577-83.
[31]
Chang M, Lee CW, Ahn JM, et al. Comparison of outcome of coronary artery bypass grafting versus drug-eluting stent implantation for non-ST-elevation acute coronary syndrome. Am J Cardiol 2017; 120: 380-6.
[32]
Mehta RH, Lopes RD, Ballotta A, et al. Percutaneous coronary intervention or coronary artery bypass surgery for cardiogenic shock and multivessel coronary artery disease? Am Heart J 2010; 159(1): 141-7.
[33]
Pi Y, Roe MT, Holmes DN, et al. Utilization, characteristics, and in-hospital outcomes of coronary artery bypass grafting in patients with ST-segment-elevation myocardial infarction: Results from the national cardiovascular data registry acute coronary treatment and intervention outcomes network registry-get with the guidelines. Circ Cardiovasc Qual Outcomes 2017; 10(8)pii e003490
[34]
Farneti PA, Sbrana S, Spiller D, et al. Reduction of blood coagulation and monocyte-platelet interaction following the use of a minimal extracorporeal circulation system (Synergy) in coronary artery bypass grafting (CABG). Perfusion 2008; 23: 49-56.
[35]
van Boven WJ, Gerritsen WB, Zanen P, et al. Pneumoproteins as a lung-specific biomarker of alveolar permeability in conventional on-pump coronary artery bypass graft surgery vs. mini-extracorporeal circuit: a pilot study. Chest 2005; 127: 1190-5.
[36]
Yilmaz A, Sjatskig J, van Boven WJ, et al. Combined coronary artery bypass grafting and aortic valve replacement with minimal extracorporeal closed circuit circulation versus standard cardiopulmonary bypass. Interact Cardiovasc Thorac Surg 2010; 11: 754-7.
[37]
Gaudino M, Taggart D, Suma H, et al. The choice of conduits in coronary artery bypass surgery. J Am Coll Cardiol 2015; 66(15): 1729-37.
[38]
Fiore AC, Naunheim KS, Dean P, et al. Results of internal thoracic artery grafting over 15 years: single versus double grafts. Ann Thorac Surg 1990; 49(2): 202-8; Discussion 08-9.
[39]
Loop FD, Lytle BW, Cosgrove DM, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med 1986; 314(1): 1-6.
[40]
Otsuka F, Yahagi K, Sakakura K, et al. Why is the mammary artery so special and what protects it from atherosclerosis? Ann Cardiothorac Surg 2013; 2(4): 519-26.
[41]
He GW, Fan L, Grove KL, et al. Expression and function of endothelial nitric oxide synthase messenger RNA and protein are higher in internal mammary than in radial arteries. Ann Thorac Surg 2011; 92(3): 845-50.
[42]
Canham PB, Finlay HM, Boughner DR. Contrasting structure of the saphenous vein and internal mammary artery used as coronary bypass vessels. Cardiovasc Res 1997; 34(3): 557-67.
[43]
Takagi H, Goto SN, Watanabe T, et al. A meta-analysis of adjusted hazard ratios from 20 observational studies of bilateral versus single internal thoracic artery coronary artery bypass grafting. J Thorac Cardiovasc Surg 2014; Oct 148(4): 1282-90.
[44]
Gaudino M, Di Franco A, Rahouma M, et al. Unmeasured confounders
in observational studies comparing bilateral versus single
internal thoracic artery for coronary artery bypass grafting: A Meta-
Analysis. J Am Heart Assoc 2018; 7(1)pii: e008010
[http://dx.doi.org/10.1161/JAHA.117.008010. Review.]
[http://dx.doi.org/10.1161/JAHA.117.008010. Review.]
[45]
Kurlansky P. Thirty-year experience with bilateral internal thoracic artery grafting: where have we been and where are we going? World J Surg 2010; 34(4): 646-51.
[46]
Taggart DP, D’Amico R, Altman DG. Effect of arterial revascularisation on survival: A systematic review of studies comparing bilateral and single internal mammary arteries. Lancet 2001; 358(9285): 870-5.
[47]
Ioannidis JP, Galanos O, Katritsis D, et al. Early mortality and morbidity of bilateral versus single internal thoracic artery revascularization: propensity and risk modeling. J Am Coll Cardiol 2001; 37(2): 521-8.
[48]
Taggart DP, Altman DG, Gray AM, et al. Randomized trial of bilateral versus single internal-thoracic-artery grafts. N Engl J Med 2016; 375(26): 2540-9.
[49]
ART - Randomised comparison of bilateral versus single internal thoracic coronary artery bypass graft surgery: effects on mortality at ten years follow-up in the Arterial Revascularisation Trial (ART)" have been discussed during the European Sociaty of Cardiology (ESC) Congress 2018, Munich (Germany); 25-29 August. 2018.
[50]
Gaudino M, Alexander JH, Bakaeen FG, et al. Randomized comparison of the clinical outcome of single versus multiple arterial grafts: the ROMA trial-rationale and study protocol. Eur J Cardiothorac Surg 2017; 52(6): 1031-40.
[http://dx.doi.org/10.1093/ejcts/ezx358. Review.]
[http://dx.doi.org/10.1093/ejcts/ezx358. Review.]
[51]
Canham PB, Finlay HM, Boughner DR. Contrasting structure of the saphenous vein and internal mammary artery used as coronary bypass vessels. Cardiovasc Res 1997; 34(3): 557-67.
[52]
Myers MG, Fremes SE. Prevention of radial artery graft spasm: a survey of Canadian surgical centres. Can J Cardiol 2003; 19(6): 677-81.
[53]
Gaudino M, Prati F, Caradonna E, et al. Implantation in the coronary circulation induces morphofunctional transformation of radial grafts from muscular to elastomuscular. Circulation 2005; 112(Suppl. 9): I208-11.
[54]
Deb S, Cohen EA, Singh SK, et al. for the RAPS Investigators. Radial artery and saphenous vein patency more than 5 years after coronary artery bypass surgery: Results from RAPS (Radial Artery Patency Study). J Am Coll Cardiol 2012; 60: 28-35.
[55]
Gaudino M, Alessandrini F, Pragliola C, et al. Effect of target artery location and severity of stenosis on mid-term patency of aorta- anastomosed vs. internal thoracic artery anastomosed radial artery grafts. Eur J Cardiothorac Surg 2004; 25: 424-8.
[56]
Tranbaugh RF, Dimitrova KR, Lucido DJ, et al. The second best arterial graft: a propensity analysis of the radial artery versus the free right internal thoracic artery to bypass the circumflex coronary artery. J Thorac Cardiovasc Surg 2014; 147: 133-40.
[57]
Hoffmann DM, Dimitrova KR, Lucido DJ, et al. Optimal conduit for diabetic patients: propensity analysis of radial and right internal thoracic arteries. Ann Thorac Surg 2014; 98: 30 36 discussion 36-7.
[58]
Benedetto U, Raja SG, Albanese A, et al. Searching for the second best graft for coronary artery bypass surgery: a network meta-analysis of randomized controlled trials. Eur J Cardiothorac Surg 2015; 47: 59-65.
[59]
Suma H, Takanashi R. Arteriosclerosis of the gastroepiploic and internal thoracic arteries. Ann Thorac Surg 1990; 50(3): 413-6.
[60]
Suma H. Gastroepiploic artery graft in coronary artery bypass grafting. Ann Cardiothorac Surg 2013; 2(4): 493-8.
[61]
Ochiai M, Ohno M, Taguchi J, et al. Responses of human gastroepiploic arteries to vasoactive substances: comparison with responses of internal mammary arteries and saphenous veins. J Thorac Cardiovasc Surg 1992; 104(2): 453-8.
[62]
Hirose H, Amano A, Takanashi S, et al. Coronary artery bypass grafting using the gastroepiploic artery in 1,000 patients. Ann Thorac Surg 2002; 73(5): 1371-9.
[63]
Glineur D. Importance of the third arterial graft in multiple arterial grafting strategies. Ann Cardiothorac Surg 2013; 2(4): 475-80.
[64]
Glineur D, D’Hoore W, El Khoury G, et al. Angiographic predictors of 6-month patency of bypass grafts implanted to the right coronary artery a prospective randomized comparison of gastroepiploic artery and saphenous vein grafts. J Am Coll Cardiol 2008; 51(2): 120-5.
[65]
Glineur D, D’Hoore W, de Kerchove L, et al. Angiographic predictors of 3-year patency of bypass grafts implanted on the right coronary artery system: a prospective randomized comparison of gastroepiploic artery, saphenous vein, and right internal thoracic artery grafts. J Thorac Cardiovasc Surg 2011; 142(5): 980-8.
[66]
Suzuki T, Asai T, Nota H, et al. Early and long- term patency of in situ skeletonized gastroepiploic artery after off-pump coronary artery bypass graft surgery. Ann Thorac Surg 2013; 96: 90-5.
[67]
Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996; 28: 616-26.
[68]
Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998; 97(9): 916-31.
[69]
Kim MS, Hwang HY, Kim JS, Oh SJ, Jang MJ, Kim KB. Saphenous vein versus right internal thoracic artery as a Y-composite graft: Five-year angiographic and clinical results of a randomized trial. J Thorac Cardiovasc Surg 2018; 156(4): 1424-1433.e1.
[70]
Samano N, Geijer H, Liden M, Fremes S, Bodin L, Souza D. The no-touch saphenous vein for coronary artery bypass grafting maintains a patency, after 16 years, comparable to the left internal thoracic artery: A randomized trial. J Thorac Cardiovasc Surg 2015; 150: 880-8.
[71]
Verma S, Lovren F, Pan Y, et al. Pedicled no-touch saphenous vein graft harvest limits vascular smooth muscle cell activation: The PATENT saphenous vein graft study. Eur J Cardiothorac Surg 2014; 45: 717-25.
[72]
Harskamp RE, Alexander JH, Schulte PJ, et al. Vein graft preservation solutions, patency, and outcomes after coronary artery bypass graft surgery: Follow-up from the PREVENT IV randomized clinical trial. JAMA Surg 2014; 149(8): 798-805. Erratum in: JAMA Surg. 2014 Sep; 149(9): 961.
[73]
Zenati MA, Shroyer AL, Collins JF, et al. Impact of endoscopic versus open saphenous vein harvest technique on late coronary artery bypass grafting patient outcomes in the ROOBY (Randomized On/Off Bypass) Trial. J Thorac Cardiovasc Surg 2011; 141(2): 338-44.
[74]
Sastry P, Rivinius R, Harvey R, et al. The influence of endoscopic vein harvesting on outcomes after coronary bypass grafting: a meta-analysis of 267,525 patients. Eur J Cardiothorac Surg 2013; 44: 980-9.
[75]
Meirson T, Orion E, Di Mario C, et al. Flow patterns in externally stented saphenous vein grafts and development of intimal hyperplasia. J Thorac Cardiovasc Surg 2015; 150: 871-8.
[76]
Deppe AC, Arbash W, Kuhn EW, et al. Current evidence of coronary artery bypass grafting off-pump versus on-pump: a systematic review with meta-analysis of over 16,900 patients investigated in randomized controlled trials†. Eur J Cardiothorac Surg 2016; 49(4): 1031-1041 Discussion 1041..
[77]
Apostolakis E, Papakonstantinou NA, Koniari I. Myocardial revascularization without extracorporeal circulation; Why hasn’t it convinced yet? Ann Card Anaesth 2017; 20(2): 219-25.
[78]
Soylu E, Harling L, Ashrafian H, et al. A systematic review of the safety and efficacy of distal coronary artery anastomotic devices. Eur J Cardiothorac Surg 2016; 49(3): 732-45.
[79]
Shroyer AL, Hattler B, Wagner TH, et al. Veterans affairs ROOBY-FS Group. Five-year outcomes after on-pump and off-pump coronary-artery bypass. N Engl J Med 2017; 377(7): 623-32.
[80]
Lamy A, Devereaux PJ, Prabhakaran D, et al. CORONARY Investigators. Five-Year outcomes after off-pump or on-pump coronary-artery bypass grafting. N Engl J Med 2016; 375(24): 2359-68.
[81]
Smart NA, Dieberg G, King N. Long-Term outcomes of on- versus off-pump coronary artery bypass grafting. J Am Coll Cardiol 2018; 71(9): 983-91.
[82]
Mao Z, Zhong X, Yin J, et al. Predictors associated with stroke after coronary artery bypass grafting: A systematic review. J Neurol Sci 2015; 357(1-2): 1-7.
[83]
Roach GW, Kanchuger M, Mangano CM, et al. Adverse cerebral outcomes after coronary bypass surgery. Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation Investigators. N Engl J Med 1996; 335(25): 1857-63.
[84]
Oi K, Arai H. Stroke associated with coronary artery bypass grafting. Gen Thorac Cardiovasc Surg 2015; 63(9): 487-95.
[85]
El-Chami MF, Kilgo P, Thourani V, et al. New-onset atrial fibrillation predicts long- term mortality after coronary artery bypass graft. J Am Coll Cardiol 2010; 55: 1370-6.
[86]
Filardo G, Hamilton C, Hebeler RF Jr, Hamman B, Grayburn P. New- onset postoperative atrial fibrillation after isolated coronary artery bypass graft surgery and long-term survival. Circ Cardiovasc Qual Outcomes 2009; 2: 164-9.
[87]
Wu ZK, Iivainen T, Pehkonen E, Laurikka J, Zhang S, Tarkka MR. Fibrillation in patients subjected to coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003; 126: 1477-82.
[88]
Mathew JP, Parks R, Savino JS, et al. Atrial fibrillation following coronary artery bypass graft surgery: Predictors, outcomes, and resource utilization. MultiCenter Study of Perioperative Ischemia Research Group. JAMA 1996; 276(4): 300-6.
[89]
Mariscalco G, Klersy C, Zanobini M, et al. Atrial fibrillation after isolated coronary surgery affects late survival. Circulation 2008; 118(16): 1612-8.
[90]
Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57(11): e101-98.
[91]
Philip F, Becker M, Galla J, Blackstone E, Kapadia SR. Transient post-operative atrial fibrillation predicts short and long term adverse events following CABG. Cardiovasc Diagn Ther 2014; 4(5): 365-72.
[92]
Algarni KD, Maganti M, Yau TM. Predictors of low cardiac output syndrome after isolated coronary artery bypass surgery: Trends over 20 years. Ann Thorac Surg 2011; 92: 1678-84.
[93]
Serraino GF, Marsico R, Musolino G, et al. Pulsatile cardiopulmonary bypass with intra-aortic balloon pump improves organ function and reduces endothelial activation. Circ J 2012; 76(5): 1121-9.
[94]
Sa MP, Ferraz PE, Escobar RR, et al. Prophylactic intra-aortic balloon pump in high-risk patients undergoing coronary artery bypass surgery: a meta-analysis of randomized controlled trials. Coron Artery Dis 2012; 23(7): 480-6.
[95]
Wan Y-D, Sun T-W, Kan Q-C, et al. The effects of intra-aortic balloon pumps on mortality in patients undergoing high-risk coronary revascularization: A meta-analysis of randomized controlled trials of coronary artery bypass grafting and stenting era. landoni g, ed. PLOS One 2016; 11(1): e0147291.
[96]
Holzmann MJ, Ahnve S, Hammar N, et al. Creatinine clearance and risk of early mortality in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2005; 130: 746-52.
[97]
Holzmann MJ, Hammar N, Ahnve S, et al. Renal insufficiency and long-term mortality and incidence of myocardial infarction in patients undergoing coronary artery bypass grafting. Eur Heart J 2007; 28: 865-71.
[98]
Hillis GS, Croal BL, Buchan KG, et al. Renal function and outcome from coronary artery bypass grafting: impact on mortality after a 2.3- year follow-up. Circulation 2006; 113: 1056-62.
[99]
Cooper WA, O’Brien SM, Thourani VH, et al. Impactofrenal dysfunction on outcomes of coronary artery bypass surgery: results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation 2006; 113: 1063-70.
[100]
Holzmann MJ, Gardell C, Jeppsson A, Sartipy U. Renal dysfunction and long-term risk of heart failure after coronary artery bypass grafting. Am Heart J 2013; 166(1): 142-9.
[102]
Toumpoulis IK, Anagnostopoulos CE, Derose JJ Jr, Swistel DG. The impact of deep sternal wound infection on long-term survival after coronary artery bypass grafting. Chest 2005; 127: 464-71.
[103]
Bryan CS, Yarbrough WM. Preventing deep wound infection after coronary artery bypass grafting: A review. Tex Heart Inst J 2013; 40: 125-39.
[104]
Daemen J, Kuck KH, Macaya C, et al. Multivessel coronary revascularization in patients with and without diabetes: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial. J Am Coll Cardiol 2008; 52: 1957-67.
[105]
BARI 2D Study Group, Frye RL, August P, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360(24): 2503-15.
[106]
Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol 2010; 55: 432-40.
[107]
Lima EG, Hueb W, Garcia RM, et al. Impact of diabetes on 10-year outcomes of patients with multivessel coronary artery disease in the Medicine, Angioplasty, or Surgery Study II (MASS II) trial. Am Heart J 2013; 166(2): 250-7.
[108]
Parasca CA, Head SJ, Milojevic M, et al. SYNTAX Investigators. Incidence, characteristics, predictors, and outcomes of repeat revascularization after percutaneous coronary intervention and coronary artery bypass grafting: The SYNTAX trial at 5 Years. JACC Cardiovasc Interv 2016; 9(24): 2493-507.
[109]
Abdallah MS, Wang K, Magnuson EA, et al. FREEDOM Trial Investigators. Quality of life after PCI vs. CABG among patients with diabetes and multivessel coronary artery disease: A randomized clinical trial. JAMA 2013; 310: 1581-90.
[110]
Magnuson EA, Farkouh ME, Fuster V, et al. FREEDOM Trial Investigators. Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial. Circulation 2013; 127: 820-31.
[111]
Serruys PW, Morice MC, Kappetein AP, et al. SYNTAX Investigators S. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360: 961-72.
[112]
Park SJ, Kim YH, Park DW, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med 2011; 364: 1718-27.
[113]
Mäkikallio T, Holm NR, Lindsay M, et al. NOBLE study investigators. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. Lancet 2016; 388(10061): 2743-52. [Erratum in: Lancet. 2016 Dec 3; 388]. [10061]. [: 2742. PMID: 27810312].
Related Journals
Applied Drug Research, Clinical Trials and Regulatory Affairs
Article Metrics
51
3